Focus Partners Wealth Has $5.57 Million Holdings in Neurocrine Biosciences, Inc. $NBIX

Focus Partners Wealth lowered its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 1.3% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 50,391 shares of the company’s stock after selling 687 shares during the period. Focus Partners Wealth owned approximately 0.05% of Neurocrine Biosciences worth $5,573,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the business. DE Burlo Group Inc. increased its stake in shares of Neurocrine Biosciences by 2.2% in the first quarter. DE Burlo Group Inc. now owns 4,717 shares of the company’s stock worth $522,000 after purchasing an additional 100 shares during the period. Nissay Asset Management Corp Japan ADV increased its stake in Neurocrine Biosciences by 0.9% during the first quarter. Nissay Asset Management Corp Japan ADV now owns 12,293 shares of the company’s stock valued at $1,360,000 after acquiring an additional 107 shares during the period. Sheaff Brock Investment Advisors LLC increased its stake in Neurocrine Biosciences by 4.8% during the first quarter. Sheaff Brock Investment Advisors LLC now owns 2,619 shares of the company’s stock valued at $290,000 after acquiring an additional 120 shares during the period. Aurora Investment Counsel increased its stake in Neurocrine Biosciences by 1.3% during the first quarter. Aurora Investment Counsel now owns 10,520 shares of the company’s stock valued at $1,164,000 after acquiring an additional 138 shares during the period. Finally, Illumine Investment Management LLC increased its stake in Neurocrine Biosciences by 1.5% during the first quarter. Illumine Investment Management LLC now owns 9,641 shares of the company’s stock valued at $1,066,000 after acquiring an additional 139 shares during the period. 92.59% of the stock is currently owned by institutional investors.

Insider Transactions at Neurocrine Biosciences

In other Neurocrine Biosciences news, Director Kevin Charles Gorman sold 106,322 shares of the company’s stock in a transaction on Thursday, August 7th. The stock was sold at an average price of $126.41, for a total transaction of $13,440,164.02. Following the transaction, the director owned 514,596 shares of the company’s stock, valued at approximately $65,050,080.36. This represents a 17.12% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Jude Onyia sold 59,819 shares of the company’s stock in a transaction on Wednesday, July 9th. The stock was sold at an average price of $130.46, for a total value of $7,803,986.74. Following the transaction, the insider directly owned 18,289 shares in the company, valued at approximately $2,385,982.94. This represents a 76.58% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 186,960 shares of company stock valued at $23,955,553 in the last three months. 4.80% of the stock is owned by corporate insiders.

Neurocrine Biosciences Price Performance

Shares of NBIX opened at $141.87 on Monday. The company has a market capitalization of $14.07 billion, a P/E ratio of 41.97, a PEG ratio of 1.02 and a beta of 0.28. Neurocrine Biosciences, Inc. has a one year low of $84.23 and a one year high of $154.61. The business’s 50 day simple moving average is $134.13 and its 200-day simple moving average is $121.20.

Neurocrine Biosciences (NASDAQ:NBIX) last announced its earnings results on Wednesday, July 30th. The company reported $1.06 EPS for the quarter, topping the consensus estimate of $0.98 by $0.08. The business had revenue of $687.50 million for the quarter, compared to the consensus estimate of $653.09 million. Neurocrine Biosciences had a return on equity of 13.22% and a net margin of 13.88%.Neurocrine Biosciences’s revenue was up 16.5% compared to the same quarter last year. During the same period in the previous year, the business earned $1.63 EPS. On average, sell-side analysts anticipate that Neurocrine Biosciences, Inc. will post 4.28 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on NBIX. The Goldman Sachs Group began coverage on Neurocrine Biosciences in a research note on Thursday, July 10th. They set a “buy” rating and a $182.00 price target on the stock. Piper Sandler boosted their price target on Neurocrine Biosciences from $154.00 to $175.00 and gave the company an “overweight” rating in a research note on Thursday, July 31st. Morgan Stanley upped their price objective on Neurocrine Biosciences from $158.00 to $163.00 and gave the company an “overweight” rating in a research note on Friday, September 5th. Truist Financial assumed coverage on Neurocrine Biosciences in a research note on Monday, July 21st. They issued a “buy” rating and a $163.00 price objective on the stock. Finally, Stifel Nicolaus upped their price objective on Neurocrine Biosciences from $166.00 to $174.00 and gave the company a “buy” rating in a research note on Thursday, July 31st. Eighteen investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $160.00.

Neurocrine Biosciences Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.